Pyc Therapeutics Ltd has released a press release.
ADOA Program - Presentation of Clinical Data at NOSA 2025
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- PKD Program - Presentation of Safety Data at ANZSN
- Appendix 4E
- Approval to Escalate Dosing in Kidney Disease Clinical Trial
- Approval to Progress Kidney Disease Trial to Next Stage
- Fourth Drug Program Progressing to Human Trials
Later from PYC Therapeutics
- Change of Managing Director
- Correction to Trading Halt Request
- Board and Management Changes
- ADOA Program Progressing to Multiple Dose Study
- PMS Program Data Supports Progression to Human Trials
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics